Skip to content

Interest of Ultrasonography in Electroneuromyography: Single-blind Randomised Controlled Clinical Trial

Interest of Ultrasonography in Electroneuromyography: Single-blind Randomised Controlled Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03868189
Acronym
US ENMG
Enrollment
290
Registered
2019-03-11
Start date
2019-04-04
Completion date
2020-06-11
Last updated
2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electromyoneurography

Brief summary

Echo-nerve tracking during an electroneuromyographic (ENMG) examination by identifying the optimal stimulation site would reduce the stimulation intensities delivered to the patient and thus improve the tolerance of this examination.

Interventions

OTHERElectroneuromyography with ultrasound

Patients whose electroneuromyography examination will be performed using an ultrasound

OTHERElectroneuromyography without ultrasound

Patients whose electroneuromyography examination will be performed without ultrasound (fake tracking)

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patient requiring an electroneuromyogram whose indication allows the application of a standard protocol of examination. * Patient that has given his/her free and informed consent. * Patient that signed the consent form. * Patient with an health insurance plan. * The patient is at least 18 years old (≥). * he patient is under 80 years old (≤).

Exclusion criteria

* Patient with symptoms of neuropathy during the screening. * Patient whose Neurological severity score (NSS) score is ≥ 3. * Patient whose neurological examination is abnormal and suggestive of neuropathy. * Patient presenting a pathology that could cause neuropathy (e.g. diabetes, renal failure, etc.). * Patient already participating in a category 1 research study (Jardé law). * Patient in an exclusion period determined by another study. * Patient under the protection of justice, under guardianship or under curatorship. * Patient refusing to sign the consent form. * Patient for which it is impossible to provide information about the study. * Pregnant patient, parturient, or breastfeeding.

Design outcomes

Primary

MeasureTime frameDescription
Supra-maximal stimulation intensity delivered by stimulation site on sensory nervesDay 0unit : milliampere (mA)

Secondary

MeasureTime frameDescription
Sensitivity Amplitude per collection siteDay 0unit : microvolts (uV)
Motor Amplitude per collection siteDay 0unit : Millivolts (mV)
Total number of explored musclesDay 0unit : number
Number of explored unusual musclesDay 0unit : number
Supra-maximal stimulation intensity delivered by stimulation site on the motor nervesDay 0unit : mA
Average time per explored site (total duration divided by the number of explored nerves and muscles)Day 0unit : minutes
Score of satisfactionDay 0Likert scale that range from 1 (not satisfied at all ) to 4 (totally satisfied)
Measurement of felt painDay 0Analogical visual scale of pain from 1 (no pain) to 100 (maximum pain)
Overall examination time between the beginning of the stimulation and the end of the myography examinationDay 0unit : minutes

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026